Project Details
Description
The trial is conducted in Asia, Europe, North America and South America. The aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.
| Status | Finished |
|---|---|
| Effective start/end date | 3/03/17 → 8/05/18 |
Collaborative partners
- Novo Nordisk Foundation (lead)
- Abu Dhabi Health Services Company
- Emirates Health Services
Keywords
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptide-1 Receptor Agonists
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Incretins
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Liraglutide
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.